Company Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States.
Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells.
The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer.
It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine.
The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016.
Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jan 2, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Shao-Lee Lin |
Contact Details
Address: 40 Guest Street Boston, Massachusetts 02135 United States | |
| Phone | 617 949 2680 |
| Website | cuebiopharma.com |
Stock Details
| Ticker Symbol | CUE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001645460 |
| CUSIP Number | 22978P205 |
| ISIN Number | US22978P2056 |
| Employer ID | 47-3324577 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shao-Lee Lin M.D., Ph.D. | President, Chief Executive Officer and Director |
| Lucinda Warren | Principal Fin and Accounting Off. and Chief Financial & Business Officer |
| Colin G. Sandercock J.D., MSE | Senior Vice President, General Counsel and Secretary |
| Dr. Ronald D. Seidel III, Ph.D. | Co-Founder |
| Dr. Rodolfo Jose Chaparro Ph.D. | Co-Founder |
| Dr. Steven C. Almo Ph.D. | Co-Founder and Chairman of Scientific and Clinical Advisory Board |
| Dr. Daniel G. Baker M.D., Ph.D. | Interim Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 11, 2026 | PRE 14A | Other preliminary proxy statements |
| May 1, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 1, 2026 | 8-K | Current Report |
| Apr 22, 2026 | 8-K | Current Report |
| Apr 13, 2026 | 8-K | Current Report |
| Apr 7, 2026 | 8-K | Current Report |
| Mar 31, 2026 | EFFECT | Notice of Effectiveness |
| Mar 27, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 27, 2026 | 8-K | Current Report |
| Mar 23, 2026 | UPLOAD | Filing |